Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...

Hay fever sufferers have attempted various treatments and techniques. They have tried antihistamines, nasal sprays, air ...

Dr.Thomas L. F. Montgomery Andresen joins from T-Cypher BioFollows breakthrough non-human primate data demonstrating deep ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...

The Peninsula brings the latest news from Qatar and around the world. We also cover in detail football, cricket, business, entertainment, Bollywood, Hollywood, Science, Technology, Health, Fitness and ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral presentation during the Late-Breaking ...

InflaRx N.V. (NASDAQ: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...

The Notice has no immediate effect on the listing or trading of the Company’s ordinary shares. The Company intends to monitor the bid price of its common shares and consider available options to ...

A new microfluidic technology that leverages immune cell behavior is set to transform cancer monitoring, thanks to researchers at UNIST. Led by Professor Joo Hun Kang in the Department of Biomedical ...

A patient in China with hepatocellular carcinoma survived 171 days following xenotransplantation with a genetically modified ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

Comprehensive Enterprise Evidence-Based Patient Activation Intelligence Solution Connects Healthcare Value-Based Care Strategy to Measurable Results Across Access, Referral Closure, Care Transitions, ...